We are live on ! Find out more

NYXH

Nyxoah

NYXH

Market cap $163M

1.60 USD

+0.06

3.9%

At close Updated Sep 14, 4:00 PM EDT

1 day

3.9%

5 days

-1.84%

1 month

-1.23%

3 months

3.23%

6 months

-49.21%

Year to date

-64.44%

1 year

-66.46%

5 years

-94.58%

10 years

-94.69%

About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Employees: 154

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 13.3%

Neutral 86.7%

Negative 0%

Zacks Investment Research

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah Q2 Earnings Call Highlights

Nyxoah NASDAQ: NYXH reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequentially to €2.5 million.

Nyxoah Q2 Earnings Call Highlights

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium – August 5, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2026. Financial and Operating Highlights Financials U.S. net revenue for the second quarter of 2026 was €5.2 million, 22% sequential growth over U.S. net revenue for the first quarter of 2026 Global net revenue for the second quarter of 2026 was €7.7 million, 21% sequential growth over global net revenue for the first quarter of 2026 Global net revenue for the first half of 2026 was €14.0 million, as compared to €2.4 million for the first half of 2025 Secured $110 million in aggregate financing during the second quarter of 2026.

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2026 on Wednesday, August 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah NASDAQ: NYXH used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability.

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah SA (NYXH) Analyst/Investor Day Transcript

Nyxoah SA (NYXH) Analyst/Investor Day Transcript

Nyxoah SA (NYXH) Analyst/Investor Day Transcript

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Nyxoah Announces Preliminary Results for the Second Quarter of 2026 Continued U.S. launch momentum drives second quarter global preliminary net revenue of €7.7 million CMS proposes 2027 OPPS and ASC payment increase of 12% and 15% respectively Mont-Saint-Guibert, Belgium – July 7, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating results. Second Quarter 2026 – Preliminary Sales and Market Metrics Financials Global net revenue is expected to be approximately €7.7 million in the second quarter of 2026, which reflects 21% sequential growth over the first quarter of 2026 U.S. net revenue is expected to be approximately €5.2 million in the second quarter of 2026, which reflects 22% sequential growth over the first quarter of 2026 Leading U.S. commercial indicators 55 new surgeons trained in Q2, bringing the total to 262 surgeons trained 89 new accounts activated in Q2, bringing the total to 180 active high-volume accounts 427 patients submitted under prior authorization entering Q3 Reimbursement US CMS is proposing to increase hospital reimbursement for the Genio procedure (C8011) from $31,526 to $35,414, representing an increase of $3,888 (12%) CMS is proposing to increase ASC reimbursement from $27,563 to $31,722, an increase of $4,159 (15%) Liquidity $110 million in aggregate financing secured in Q2 As of June 30, 2026, cash, cash equivalents and financial assets are expected to be approximately €97.8 million "We closed Q2 with clear U.S. momentum: the scaling of our U.S. sales force allowed us to double the number of active accounts to 180 high-volume HGNS accounts and deliver a second consecutive quarter of over 20% sequential U.S. revenue growth.

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Information on the total number of voting rights and shares

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 146,531 new shares on June 30, 2026 following the exercise of so-called “restricted share units”. Share capital: EUR 7,075,152.31 Total number of securities carrying voting rights: 100,072,815 (all ordinary shares) Total number of voting rights (= denominator): 100,072,815 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 3,731,884 (all granted subscription rights; this number excludes 36,125 subscription rights that were issued but not yet granted) Total number of convertible bonds: 225 convertible bonds with a nominal value of EUR 83,000 per bond Total number of voting rights that can be obtained in case of conversion of all 225 convertible bonds at the current (revised) conversion price of EUR 1.48 per share: 12,618,243 (this number does not take into account the conversion of interest) * * * Contact: Nyxoah John Landry, [email protected] Attachment 2026 06 30 - Press release - Number of shares (ENG)

Information on the total number of voting rights and shares

See News Rankings

Price charts implemented using Lightweight Charts™